Detail akcie Psychemedics online

Business Summary: Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Psychemedics Corp. revenues decreased 12% to $22.1M. Net loss increased from $1.1M to $4.2M. Revenues reflect Testing segment decrease of 14% to $18.7M, Shipping Collection Hair segment decrease of 5% to $3.3M, United States segment decrease of 13% to $21.2M. Higher net loss reflects Other General & Administrative increase of 23% to $6.4M (expense).